SKI Market

A+| A| A-|

Indian Indices

Sensex

74,198.78 879.23
( 1.20%)

Global Indices

Nasdaq

46,525.67 -61.07
(-0.13%)

Dow Jones

6,603.69 7.37
(0.11%)

Hang Seng

53,576.26 452.77
(0.85%)

Nikkei 225

10,436.29 71.50
(0.69%)

Forex

USD-INR

93.02 -0.15
(-0.16%)

EUR-INR

107.32 -0.65
(-0.60%)

GBP-INR

123.03 -0.78
(-0.63%)

JPY-INR

0.58 0.00
(-0.67%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Aurobindo Pharma Ltd

Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln

BSE Code

ISIN Demat

Book Value()

524804

INE406A01037

369.1611632

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

AUROPHARMA

36.19

77592.19

EPS(TTM)

Face Value()

Div & Yield %

36.91

Back

colab platforms ltd

Ruby Mills standalone net profit rises 292.50% in the September 2025 quarter

Nov 14,2025

Net profit of Ruby Mills rose 292.50% to Rs 10.99 crore in the quarter ended September 2025 as against Rs 2.80 crore during the previous quarter ended September 2024. Sales rose 66.68% to Rs 85.64 crore in the quarter ended September 2025 as against Rs 51.38 crore during the previous quarter ended September 2024.

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	85.64	51.38	67
OPM %	18.79	9.60	-
PBDT	17.20	6.34	171
PBT	14.40	3.47	315
NP	10.99	2.80	293

74,198.78 879.23 ( 1.20%)

46,525.67 -61.07 (-0.13%)

6,603.69 7.37 (0.11%)

53,576.26 452.77 (0.85%)

10,436.29 71.50 (0.69%)

93.02 -0.15 (-0.16%)

107.32 -0.65 (-0.60%)

123.03 -0.78 (-0.63%)

0.58 0.00 (-0.67%)